Abuse-resistant drugs a growing niche

PharmTech.com notes that abuse-resistant pain drugs are a hot area of development right now. Author Patrician Van Arnum brings up Pfizer's recent $3.6 billion purchase of King Pharmaceuticals for its drug-delivery technology that discourages abuse of painkillers. The article provides a decent overview of King's pipeline of abuse-deterrent medication and the reason for Pfizer's interest. "King's leadership in new formulations of pain treatments designed to discourage common methods of misuse and abuse will provide Pfizer with multiple drug-delivery platforms while providing potential long-term upside," Pfizer said in a release in October. PharmTech's report

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.